Close

Mizuho Securities Remains Bullish on Mallinckrodt (MNK) Following Strong 4Q

Go back to Mizuho Securities Remains Bullish on Mallinckrodt (MNK) Following Strong 4Q

Mallinckrodt (MNK) Sees Notable Pressure

November 29, 2016 9:52 AM EST

Mallinckrodt (NYSE: MNK) is seeing notable weakness following earning this morning. The call is ongoing. Shares are down 6.6%

... More

BMO Capital Reiterates Outperform on Mallinckrodt (MNK) Following Solid 4Q

November 29, 2016 9:43 AM EST

BMO Capital reiterated an Outperform rating and $92.00 price target on Mallinckrodt plc (NYSE: MNK) following the company's 4Q earnings report. Revenue of $887mn came in ahead of the consensus of 874mn, driven largely by Acthar. EPS were $2.04 vs. the consensus of 1.97.... More

Health stocks boost Wall Street; energy a drag

November 29, 2016 7:33 AM EST

By Caroline Valetkevitch

(Reuters) - U.S. stocks edged higher on Tuesday as an upbeat outlook from UnitedHealth lifted health insurers, though a sharp drop in oil prices weighed on energy shares and limited the advance.

The day's small gains followed a decline in the market on Monday. Analysts said the post-U.S. election rally may be losing momentum, wit the S&P 500 now up roughly 8 percent for the year to date.

Wall Street has risen sharply following Donald Trump's White House win, helped in part by investor expectations that his plans to increase infrastructure spending,... More

Mallinckrodt (MNK) Tops Q4 EPS by 3c; Therakos Production Issues Noted

November 29, 2016 6:01 AM EST

Mallinckrodt (NYSE: MNK) reported Q4 EPS of $2.04, $0.03 better than the analyst estimate of $2.01. Revenue for the quarter came in at $887.2 million versus the consensus estimate of $880.1 million.

H.P. Acthar Gel (repository corticotropin injection) net sales were $327.0 million in the quarter, a 19.3% increase over $274.2 million. Mallinckrodts second largest product, INOMAX (nitric oxide) gas, for inhalation, generated net sales of $126.9 million, up 22.4% over $103.7 million, with constant-currency growth of 22.4%. In the quarter the U.S. Patent and Trademark Office and its Patent Trial and Appeal Board affirmed the validity of multiple INOMAX drug and device... More

Mallinckrodt Plc (MNK) December weekly 57 straddle priced for movement of 9.6%

November 28, 2016 3:10 PM EST

Mallinckrodt (NYSE: MNK) December weekly 57 straddle priced for movement of 9.6%

... More

Trading Radar for 11/29: BNS (BNS), Tiffany (TIF), Autodesk (ADSK), Splunk (SPLK) Report

November 28, 2016 1:30 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:30am EST

GDP - Second Estimate - Street sees 3.0%GDP Deflator: Second Estimate - Street sees 1.5%

9:00am EST

Case-Shiller 20-City Index - Street sees... More

Mallinckrodt Plc (MNK) volatility increases to into Q4

November 28, 2016 11:39 AM EST

Mallinckrodt (NYSE: MNK) December weekly call option implied volatility is at 106, December is at 77; compared to its 52-week range of 34 to 97 into the expected release of Q4 results on November 29.

... More